Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Treadwell Therapeutics, Inc, active and no longer recruiting.
Overview
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT04521413 by Treadwell Therapeutics, Inc, with 170 participants enrolled, started 2020-08-31 and due to reach its primary completion in 2025-11. Interventions recorded: CFI-402411 and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialCFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Shares Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of YL242 in Subjects With Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialN-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.